Wegovy and Pregnancy Registries: What the Evidence Says and Why It Matters

What animal and early human data actually tell us

The honest answer is that human evidence on semaglutide in pregnancy is thin, and that is exactly why a dedicated pregnancy exposure registry exists. Animal reproduction studies, conducted by Novo Nordisk as part of the regulatory approval process, showed adverse developmental effects at doses within the range relevant to humans. Those findings were serious enough for the MHRA and regulatory bodies worldwide to require a clear contraindication during pregnancy in the Wegovy prescribing information (SmPC), which you can review directly on the Electronic Medicines Compendium.

What animal studies cannot do is predict human outcomes with precision. The biology differs, and the doses used in preclinical testing do not map cleanly onto a weekly 2.4mg injection in a person. That gap is why regulators asked Novo Nordisk to establish a structured observational programme to collect real-world pregnancy outcome data, the Semaglutide Pregnancy Exposure Registry.

As of mid-2026, the registry is still accumulating cases. No large-scale human trial has deliberately enrolled pregnant participants, that would be ethically impossible. So the evidence base remains the SmPC, early observational signals, and the expanding registry. Clinicians are clear that the absence of reassuring data is not the same as a green light; the guidance stays as it is until the registry provides a different picture.

What happens if you become pregnant while taking Wegovy

A question our prescribers hear most weeks is what to do if a positive test appears mid-treatment. The steps are straightforward, even if the situation feels alarming.

Stop Wegovy as soon as you know you are pregnant. There is no taper required, simply discontinuing is the right move. Contact your GP promptly so that your pregnancy can be overseen appropriately from the start, and inform whoever prescribed your Wegovy, whether that is a specialist clinic or a private service like our clinical team. Your prescriber should notify Novo Nordisk's pregnancy registry on your behalf, though you can also enrol directly; the Yellow Card scheme at yellowcard.mhra.gov.uk is the UK channel for reporting unexpected medicine exposure during pregnancy.

The semaglutide half-life matters here. After stopping, it takes roughly five weeks for the medicine to clear from your system, it is a long-acting compound. That does not mean harm is inevitable if the first few weeks of pregnancy overlapped with treatment, but it is information your midwifery team and GP need to have.

If you have questions about how Wegovy can affect pregnancy, including what the evidence says about exposure in early gestation, that detail is covered in full for anyone who wants to go deeper before speaking to a clinician.

For anyone thinking more broadly about Wegovy and pregnancy, the picture is about timing and planning rather than permanent exclusion from treatment.

Stopping before conception: what the wash-out period means in practice

If you are on Wegovy and planning a pregnancy, the recommendation is to stop treatment at least two months before trying to conceive. That two-month figure reflects the long half-life of semaglutide and is consistent with the MHRA's position on GLP-1 medicines and contraception, detailed at gov.uk/drug-safety-update. Stopping two months out gives the medicine time to clear and reduces the window of exposure during early embryonic development.

That wash-out period has a practical implication for weight management. Some people find that weight regain begins fairly quickly after stopping a GLP-1 medicine, the appetite-suppressing effect goes with the medicine. Anyone who wants to understand what using Wegovy before pregnancy means for their weight and treatment plan, including how to time stopping and what to expect during the transition, will find that covered in detail. Planning the transition thoughtfully matters.

The broader question of pregnancy after Wegovy (including what weight-management support looks like once treatment has stopped) is something to plan well ahead of conception, not in the week of the positive test. If you are not yet at that planning stage and are considering whether Wegovy is the right treatment for you, our free consultation is the place to start that conversation with a clinician.

Oral semaglutide, Ozempic, and the same rules

The same not-recommended-in-pregnancy guidance applies to oral semaglutide (Wegovy tablets, approved by the MHRA in June 2026 as the first oral GLP-1 for weight management) and to Ozempic, the injectable semaglutide licensed for type 2 diabetes. The active compound is the same; the route of administration does not change the reproductive safety picture. Anyone reading about semaglutide and pregnancy more broadly should know this applies across all semaglutide formulations.

Ozempic is not licensed for weight loss in the UK (the MHRA is clear on that distinction) but women managing type 2 diabetes with Ozempic face the same pregnancy considerations. Their diabetes specialist needs to be involved, because the interaction between blood-glucose management and pregnancy is its own clinical priority.

If you are currently on Wegovy for weight management and have questions about contraception while on treatment, guidance on effective contraception alongside GLP-1 therapy is available through the Wegovy overview page, and your prescriber can advise on what suits your situation specifically.